If you are wondering whether Moderna's share price really reflects what the business is worth today, you are not alone. That ...

European Medicines Agency approves Moderna's mRNA flu vaccine with strong efficacy in older adults. US FDA initially declines to review the same vaccine despite positive clinical trial data. Moderna's ...

Piper Sandler expects Moderna to generate $2.07 billion in product sales in 2026, driven largely by its next‑generation COVID vaccine, mNEXSPIKE, according to Investing.com. The FDA is set to review ...

Moderna (MRNA) is back in focus after completing a clinical study of multiple mRNA vaccines targeting several respiratory diseases, alongside fresh regulatory attention on mRNA products from U.S.